Current migraine treatment guidelines center on two parallel tracks: stopping attacks when they happen and, for people with frequent episodes, preventing them from occurring in the first place. The acute side relies primarily on anti-inflammatory painkillers and triptans, chosen based on attack severity rather than tried in a fixed sequence. The preventive side has expanded considerably with the arrival of therapies that target calcitonin gene-related peptide (CGRP), which several guideline bodies now consider a first-line option alongside older oral preventives. The landscape has shifted enough in recent years that strategies written even five years ago look incomplete.
Acute Treatment and the Stratified Care Approach
For a long time, doctors were taught to manage migraine attacks in a stepwise fashion: start with a simple painkiller, and if that doesn’t work over multiple attacks, escalate to something stronger. That approach sounds sensible but performs poorly in practice. A landmark randomized trial compared this “step care” model against “stratified care,” where the doctor picks the drug based on how disabling the patient’s attacks typically are. Stratified care produced a headache response rate of about 53% across attacks, compared with roughly 37 to 41% for either version of step care, and patients spent significantly less time disabled.
Guidelines from the European Federation of Neurological Societies and multiple headache societies now recommend this stratified model. In practical terms, that means people with mild-to-moderate attacks that don’t interfere much with daily life can start with over-the-counter anti-inflammatory drugs like ibuprofen or aspirin. Those whose attacks are more severe, or who haven’t responded to anti-inflammatories in the past, should go straight to a triptan or another migraine-specific agent.
One detail that often gets overlooked: European guidelines specifically recommend taking an anti-nausea drug such as metoclopramide or domperidone before the painkiller or triptan, not because nausea is dangerous on its own, but because the stomach slows down during a migraine attack, which means oral drugs absorb poorly.
Triptans, NSAIDs, and Newer Acute Options
Triptans remain the backbone of acute migraine treatment for moderate-to-severe attacks. Seven triptans are available, and while they share the same mechanism, they differ in speed of onset, route of delivery, and how long they last. Subcutaneous sumatriptan works the fastest but also has the most side effects; oral formulations are gentler but slower. For people who vomit early in an attack, nasal sprays and injections bypass the stomach entirely.
NSAIDs, especially ibuprofen, naproxen, and aspirin, are recommended as first-line for milder attacks. European guidelines also endorse intravenous aspirin for very severe episodes in a clinical setting.
Two newer drug classes have entered the acute treatment picture. Lasmiditan, a serotonin receptor agonist that works differently from triptans, does not constrict blood vessels, which matters for people with heart disease or stroke history. A review of cardiovascular safety data found no cardiovascular concerns with lasmiditan, making it a viable option for patients who cannot use triptans.
Gepants, small-molecule CGRP receptor antagonists available in oral form, can treat an acute attack and also be used preventively. Ubrogepant and rimegepant are approved for acute use. Because they don’t carry the same vascular restrictions as triptans, they fill an important gap for people with cardiovascular risk factors, though the evidence base for their long-term cardiovascular safety is still building.
What the Emergency Department Guidelines Say
When a migraine is severe enough to send someone to the emergency room, the treatment toolkit looks quite different from what you’d use at home. The 2025 American Headache Society update on emergency department management identifies intravenous prochlorperazine and greater occipital nerve blocks as the strongest-evidence interventions, recommending they “must be offered” to eligible patients. IV ketorolac, IV metoclopramide, and subcutaneous sumatriptan all received “should offer” recommendations.
Equally striking is what the guidelines say to avoid. Intravenous hydromorphone, an opioid, was found likely ineffective for migraine and received a “must not offer” designation. An earlier version of these guidelines had already flagged that injectable opioids like morphine and hydromorphone should be avoided as first-line therapy due to both poor efficacy and risk of worsening the cycle of headache.
Dexamethasone, a corticosteroid, doesn’t do much for the current headache but has a specific role: it reduces the chance of the migraine bouncing back within a few days. Earlier guidelines recommended it specifically for that purpose.
Preventive Treatment and Who Should Get It
Not everyone with migraine needs preventive medication. The general threshold is around four or more migraine days per month, or fewer if the attacks are particularly disabling or difficult to treat acutely. The decision is also influenced by whether acute medications are being overused, since frequent painkiller use can itself fuel a worsening cycle of headache.
The traditional oral preventives have been around for decades. A 2025 systematic review from the American Academy of Neurology and the American Headache Society graded the evidence and found moderate-confidence support for propranolol, topiramate, and valproate in episodic migraine prevention. Several other agents, including amitriptyline, metoprolol, and flunarizine, showed possible benefit but with lower-confidence evidence. None of these were originally developed for migraine; they are borrowed from cardiology, psychiatry, and epilepsy treatment, and their side-effect profiles reflect those origins. Propranolol can cause fatigue and cold hands, topiramate can cause cognitive dulling and weight loss, and valproate carries serious risks in pregnancy.
For chronic migraine, defined as fifteen or more headache days per month with at least eight meeting migraine criteria, the evidence picture changes somewhat. OnabotulinumtoxinA (Botox) was FDA-approved for chronic migraine prevention in 2010 and has accumulated a substantial evidence base showing reductions in headache frequency and severity. European guidelines recommend it as an effective and well-tolerated option specifically for chronic migraine, administered as a series of injections across the head and neck every twelve weeks.
CGRP-Targeting Therapies as First-Line Prevention
The biggest shift in migraine prevention over the past several years has been the rise of treatments that target CGRP, a signaling molecule heavily involved in migraine pain. Four monoclonal antibodies given by injection (erenumab, fremanezumab, galcanezumab, and eptinezumab) and oral gepants (atogepant and rimegepant) are now available for prevention.
The American Headache Society updated its position in 2024 to state that CGRP-targeting therapies should be considered first-line for migraine prevention, alongside previous first-line treatments, without requiring patients to fail other drug classes first. That is a meaningful change from earlier guidelines that positioned these newer drugs as second- or third-line options. The 2025 AAN systematic review found moderate-confidence evidence supporting atogepant, eptinezumab, and fremanezumab for episodic migraine, and high-confidence evidence supporting fremanezumab, galcanezumab, and onabotulinumtoxinA for chronic migraine. The European Headache Federation similarly found moderate to high quality evidence for all four CGRP monoclonal antibodies in both episodic and chronic migraine.
Not every country treats these therapies the same way. A 2025 global comparison of migraine guidelines found that American and Japanese guidelines position CGRP monoclonal antibodies and gepants as first-line, while British and French guidelines restrict access, typically requiring failure of several oral preventives before approval. The differences stem largely from drug availability and insurance coverage rather than disagreements about the science itself.
Cost-Effectiveness and Access
The clinical enthusiasm for CGRP therapies runs into a practical wall: cost. A cost-effectiveness analysis of erenumab found it was a cost-effective strategy for chronic migraine patients compared with no preventive treatment and compared with onabotulinumtoxinA, but was less likely to represent good value for people with episodic migraine unless lost productivity costs were factored in. A systematic review of economic evaluations for chronic migraine treatments found that onabotulinumtoxinA was cost-effective compared with placebo, while the CGRP antibodies were cost-effective mainly among patients who had already failed other treatments including Botox.
The oral gepants face an even steeper cost hurdle for preventive use. A US societal-perspective analysis found that atogepant yielded an incremental cost-effectiveness ratio above $450,000 per quality-adjusted life year compared with placebo, and rimegepant above $890,000, both far exceeding standard willingness-to-pay thresholds. These numbers matter because they drive insurance formulary decisions and prior authorization requirements, which in turn determine whether patients can actually access the treatments their doctors prescribe.
Medication Overuse Headache
One of the trickiest aspects of migraine management is the paradox that the very medications used to treat attacks can, if used too frequently, make headaches worse and more frequent. This is called medication overuse headache, and it affects a substantial minority of chronic migraine patients. European Academy of Neurology guidelines recommend that the first step is education: simply informing patients about the link between frequent painkiller use and worsening headaches can be enough for some people to self-correct.
When education alone isn’t sufficient, the guidelines recommend withdrawing the overused drug and starting preventive treatment simultaneously. For simple analgesics, triptans, and ergots, abrupt withdrawal is acceptable. For opioids, barbiturates, and tranquilizers, a slow taper is recommended to avoid withdrawal complications. This withdrawal can happen as an outpatient for most people, though day-care or inpatient settings are sometimes necessary for complex cases.
Migraine During Pregnancy and Breastfeeding
Migraine treatment in pregnancy is an area where guidelines are unusually conservative, and for good reason. Non-drug approaches are always the first-line recommendation. When medication is necessary, paracetamol (acetaminophen) is the preferred acute treatment throughout pregnancy. If paracetamol is not effective enough, occasional use of sumatriptan can be considered, as the accumulated safety data for sumatriptan in pregnancy is more reassuring than for other triptans. NSAIDs like ibuprofen can be used in the second trimester but carry specific risks in the first and third trimesters.
Preventive treatment during pregnancy should only be considered in the most severe cases. Some historically routine options have become more controversial: recent safety discussions have raised questions about magnesium supplementation, acetaminophen itself at high cumulative exposure, ondansetron (often used for nausea), and butalbital. These concerns don’t necessarily mean these treatments are dangerous, but they add complexity to decision-making.
For breastfeeding, the primary consideration is whether the drug transfers into breast milk in meaningful quantities. Understanding which treatments are compatible with breastfeeding allows women to continue nursing while managing their migraine, which is relevant because migraine often returns after delivery once the protective hormonal environment of late pregnancy fades.
Migraine in Children and Adolescents
Pediatric migraine treatment follows its own evidence base, and the options are narrower than for adults. An American Academy of Neurology practice guideline update found evidence supporting ibuprofen and acetaminophen for acute treatment in both children and adolescents, and triptans mainly in adolescents. Among the triptans studied in younger patients, oral sumatriptan combined with naproxen and zolmitriptan nasal spray had the strongest evidence, with high confidence that adolescents taking these were more likely to be headache-free at two hours compared with placebo.
For prevention in children and adolescents, behavioral interventions play a larger role than they do in adults, partly because the evidence for preventive medications in this age group is weaker and the tolerance for side effects lower. A systematic review found that the combination of cognitive behavioral therapy, biofeedback, and relaxation training may reduce migraine frequency and disability more than education alone in younger patients, though the overall evidence quality remains low.
Menstrual Migraine
Menstrually related migraine affects a large subset of women with migraine and follows a predictable pattern tied to estrogen withdrawal around the time of menstruation. Because the timing is predictable, short-term “mini-prevention” strategies can be deployed around the vulnerable window rather than taking a preventive drug every day of the month. An evidence-based review found grade B recommendations for perimenstrual use of transcutaneous estrogen, frovatriptan taken twice daily, and naratriptan taken twice daily during the menstrual window. These short-course preventive strategies are specific to menstrual migraine and represent a distinct treatment approach not typically covered in general migraine prevention guidelines.
Behavioral and Non-Drug Interventions
Non-pharmacological treatments are consistently recommended across all guidelines as a complement to medication, and in some populations (pregnant women, children, people who prefer to avoid drugs) as the primary strategy. The evidence base, however, varies by technique.
Biofeedback, which teaches people to control physiological responses like muscle tension and skin temperature, significantly reduced headache frequency and severity compared with no treatment in a meta-analysis, though it performed no better than active treatments like medication or cognitive behavioral therapy. That positions it as a legitimate alternative for people who want or need to avoid drugs, rather than a superior strategy.
A large systematic review of behavioral interventions for migraine prevention encompassing fifty trials in adults found that cognitive behavioral therapy, relaxation training, and mindfulness-based therapies may each reduce migraine frequency, though the evidence for all three was rated as low confidence. Relaxation training combined with education may improve migraine-related quality of life more than propranolol, a standard preventive medication, which is a noteworthy finding even at low evidence strength. For children and adolescents, as noted earlier, the combination of cognitive behavioral therapy with biofeedback and relaxation training showed the most promise.
Supplements With Some Evidence
Several dietary supplements appear in migraine guidelines, usually with cautious language. Magnesium, riboflavin (vitamin B2), and coenzyme Q10 are the most commonly mentioned. A randomized, placebo-controlled trial of a supplement combining all three found a trend toward reduced migraine frequency that did not quite reach statistical significance, but did find statistically significant reductions in migraine symptoms and overall disease burden compared with placebo. Academic reviews have emphasized that while the rationale for these supplements is biologically plausible, larger and more rigorous trials are still needed to confirm their individual and combined effects.
The appeal of supplements is obvious: they are inexpensive, widely available, and carry few side effects compared with prescription preventives. Guidelines generally position them as reasonable options for patients with infrequent migraine who want to try something before committing to a daily prescription, or as add-ons to prescription treatment.
Neuromodulation Devices
A growing category of migraine treatment involves non-invasive devices that deliver electrical or magnetic stimulation to nerves or brain regions involved in migraine. The International Headache Society published evidence-based guidelines in 2025 evaluating these devices. Weak recommendations were issued for several specific devices in acute treatment (including external trigeminal nerve stimulation and remote electrical neuromodulation) and for prevention. The word “weak” in evidence-grading language does not mean “don’t bother”; it means the evidence suggests benefit but is not yet strong enough for a firm endorsement.
For patients who cannot tolerate medications, who are pregnant, or who simply prefer a drug-free approach, these devices represent a growing option. Their practical limitations include cost (most are not covered by insurance), the need for consistent use, and the fact that effect sizes in trials tend to be modest.
Why Timing and Adherence Shape Outcomes
One finding that cuts across every treatment guideline is that how and when you take acute medication matters as much as which medication you take. A daily diary study found that taking migraine-specific medication while pain was still mild was associated with the lowest disability scores and highest patient satisfaction. Waiting until pain progressed to moderate or severe intensity before dosing was a common pattern and consistently produced worse results.
Adherence to both acute and preventive medication is poor in the real world. A study of migraine patients in China found that only about 31% showed good adherence to acute medication, with the most common non-adherent behavior being simply not taking anything during an attack. The most frequently cited reason was believing the headache was too mild to warrant medication, followed by fear of side effects. Those with good adherence averaged roughly 3.4 headache days per month, compared with about 7.7 days for non-adherent patients.
Preventive medication adherence tells a related story. Among patients prescribed fremanezumab, a CGRP monoclonal antibody given by self-injection, about 75% were adherent over six months. Quarterly dosing was associated with higher adherence rates than monthly dosing, which makes intuitive sense: fewer injections means fewer opportunities to skip one. Patients who stuck with the treatment for at least six months saw significant reductions in their need for acute migraine prescriptions.